News

Opus Genetics, a patient-first, clinical-stage gene therapy company developing treatments for inherited retinal diseases, announced it has acquired the rights to two preclinical-stage…
Read More...

Gilead Sciences, Inc. and Jounce Therapeutics, Inc. amended their existing license agreement for GS-1811, enabling Gilead to buy out remaining contingent payments potentially due under…
Read More...

AstraZeneca’s immunotherapies Imfinzi (durvalumab) and Imjudo (tremelimumab) have been approved in Japan for the treatment of three cancer types: advanced liver, biliary tract and lung.…
Read More...

Following the formation of Mayflower Bioventures, a cell and gene therapy accelerator stood up from Hibiscus BioVentures and Mayo Clinic, comes the launch of their first start-up,…
Read More...

Global biotechnology leader CSL announced that the U.S. Food and Drug Administration (FDA) approved HEMGENIX (etranacogene dezaparvovec-drlb), the first and only one-time gene therapy…
Read More...

Berkeley Lights, a life sciences tools company, and IsoPlexis, a company empowering labs to leverage the cells and proteome changing the course of human health, announced a definitive…
Read More...

Skye Bioscience, Inc., a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, announced that the U.S. Food and Drug Administration…
Read More...

Kite, a Gilead Company and Tmunity Therapeutics (Tmunity) announced that the companies have signed an agreement in which Kite will acquire Tmunity, a clinical-stage, private biotech…
Read More...

Sanofi and Innate Pharma SA announced an expansion of their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3 from Innate’s ANKETTM …
Read More...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the treatment of adult patients with advanced…
Read More...

BIOASIS TECHNOLOGIES INC., a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and a differentiated,…
Read More...

Fresenius Kabi announced the immediate availability in the U.S. of Lacosamide Injection, USP, a generic equivalent to VIMPAT. Fresenius Kabi Lacosamide Injection, USP is an approved…
Read More...

Gilgamesh Pharmaceuticals, a biotechnology company developing a portfolio of rapid-acting and durable treatments for depression and other mental health disorders, announced the closing…
Read More...

The European Commission (EC) has expanded the marketing authorization for Dupixent (dupilumab) in the European Union to treat adults with moderate-to-severe prurigo nodularis who are…
Read More...

Eisai Co., Ltd. announced that Eisai and Washington University School of Medicine in St. Louis have entered into a comprehensive research collaboration agreement aiming to create…
Read More...

Filament Health Corp. a clinical-stage natural psychedelic drug development company, and Psyence Group Inc, a life science biotechnology company pioneering the use of natural psilocybin…
Read More...

Ono Pharmaceutical Co., Ltd. announced that it has entered into a multi target R&D collaboration agreement with PrecisionLife Limited, a global techbio company generating the…
Read More...

Exicure, Inc. an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, announced the…
Read More...

Innovent Biologics, a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune,…
Read More...

Harrow, an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, announced that it has entered into…
Read More...